Phospho-SHC (Ser36) Antibody - #AF8232

>>赠JD卡 已结束>>
(2)   (6)  
产品: 磷酸化 SHC (Ser36) 抗体
货号: AF8232
描述: Rabbit polyclonal antibody to Phospho-SHC (Ser36)
应用: WB IHC IF/ICC
文献验证: WB, IHC
反应: Human, Mouse
预测: Horse, Dog
蛋白号: P29353
RRID: AB_2840294

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:1000-3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse
克隆:
Polyclonal
特异性:
Phospho-SHC (Ser36) Antibody detects endogenous levels of SHC only when phosphorylated at Ser36.
RRID:
AB_2840294
引用格式: Affinity Biosciences Cat# AF8232, RRID:AB_2840294.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

FLJ26504; p66; p66SHC; SH2 domain protein C1; SHC (Src homology 2 domain containing) transforming protein 1; SHC 1; SHC A; SHC adaptor protein 1; Shc; SHC transforming protein 1; SHC transforming protein; SHC-transforming protein 1; SHC-transforming protein 3; SHC-transforming protein A; SHC1; SHC1_HUMAN; SHCA; Src homology 2 domain-containing-transforming protein C1;

抗原和靶标

免疫原:

A synthesized peptide derived from human SHC around the phosphorylation site of Ser36.

基因/基因ID:
SHC1(6464)

研究领域

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

文献引用

1). VDR alleviates endothelial cell injury in arteriovenous fistula through inhibition of P66Shc-mediated mitochondrial ROS. Scientific reports, 2023 (PubMed: 37422508) [IF=3.8]

Application: WB    Species: Human    Sample:

Figure 2 The expression of VDR, P66Shc, P-P66Shc and oxidative stress, fibrosis paramaters in AVF stenosis vessels. (A) IHC staining of VDR (left panels, magnification 20 × , right panel, magnification 400 ×) in the AVF stenosis patients and control subjects. (B) IHC staining of P66Shc (left panel), P-P66Shc (middle panel) and oxidative stress parameter, 8-ohdG (right panel) of two groups. (C) Western blot analysis of FN (upper panel), Col-1, P66Shc, P-P66Shc(middle panel) and VDR (bottom panel) protein expression in AVF vascular tissue of two groups . (D) Semiquantitative analysis of IHC stained with 8-ohdG, *P 

Application: IHC    Species: Human    Sample:

Figure 2 The expression of VDR, P66Shc, P-P66Shc and oxidative stress, fibrosis paramaters in AVF stenosis vessels. (A) IHC staining of VDR (left panels, magnification 20 × , right panel, magnification 400 ×) in the AVF stenosis patients and control subjects. (B) IHC staining of P66Shc (left panel), P-P66Shc (middle panel) and oxidative stress parameter, 8-ohdG (right panel) of two groups. (C) Western blot analysis of FN (upper panel), Col-1, P66Shc, P-P66Shc(middle panel) and VDR (bottom panel) protein expression in AVF vascular tissue of two groups . (D) Semiquantitative analysis of IHC stained with 8-ohdG, *P 
2). Mitochondrial Translocation of P66Shc Aggravates Cisplatin-induced AKI by Promoting Ferroptosis. Current medicinal chemistry, 2023 (PubMed: 35986536) [IF=3.5]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.